null Kevin Schwartzman, MD MPH

Senior Scientist, RI-MUHC, 5252 de Maisonneuve site

Translational Research in Respiratory Diseases Program

Centre for Outcomes Research and Evaluation

Professor, Department of Medicine, Faculty of Medicine and Health Sciences, McGill University

Department of Medicine, Division of Respiratory Medicine, MUHC



tuberculosis • epidemiology • public health • respiratory disease • health economics • digital adherence technologies

Research Focus

My research focuses on designing more effective and cost-effective interventions for tuberculosis care and prevention, using predictions based on current knowledge of benefits, costs, and impacts including those on patients' quality of life. My current research focuses on potential tuberculosis prevention strategies for migrants to Canada using computer simulation techniques. I also consider ethical dimensions of these strategies.

Research initiative
Tuberculosis in Canada: Modeling to Inform Elimination

Selected Publications

Click on Pubmed to see my current publications list

  • Domestic returns from investment in the control of tuberculosis in other countries. Schwartzman K, Oxlade O, Barr RG, Grimard F, Acosta I, Baez J, Ferreira E, Melgen RE, Morose W, Salgado AC, Jacquet V, Maloney S, Laserson K, Mendez AP, Menzies D. N Engl J Med. 2005 Sep 8;353(10):1008-20. doi: 10.1056/NEJMsa043194. PMID: 16148286.

  • The potential impact and cost-effectiveness of tobacco reduction strategies for tuberculosis prevention in Canadian Inuit communities. N'Diaye DS, Nsengiyumva NP, Uppal A, Oxlade O, Alvarez GG, Schwartzman K. BMC Med. 2019 Feb 4;17(1):26. doi: 10.1186/s12916-019-1261-5. Free PMC article. PMID: 30712513.

  • Treatment of latent infection to achieve tuberculosis elimination in low-incidence countries. Campbell JR, Dowdy D, Schwartzman K. PLoS Med. 2019 Jun 6;16(6):e1002824. doi: 10.1371/journal.pmed.1002824. eCollection 2019 Jun. Free PMC article. Review. PMID: 31170161.

  • Active screening for tuberculosis in high-incidence Inuit communities in Canada: a cost-effectiveness analysis. Uppal A, Nsengiyumva NP, Signor C, Jean-Louis F, Rochette M, Snowball H, Etok S, Annanack D, Ikey J, Ahmad Khan F, Schwartzman K. CMAJ 2021; 193 (43) E1652-E1659; DOI: PMID: 34725112.

  • Scaling up target regimens for tuberculosis preventive treatment in Brazil and South Africa: An analysis of costs and cost-effectiveness. Nsengiyumva NP, Campbell JR, Oxlade O, Vesga JF, Lienhardt C, Trajman A, Falzon D, Den Boon S, Arinaminpathy N, Schwartzman K. PLoS Med. 2022 Jun 13;19(6):e1004032. doi: 10.1371/journal.pmed.1004032. PMID: 35696431.